Health TrialsbyHealthPanel

Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)

ConditionsBorderline Personality Disorder (BPD)Treatment-Resistant Major Depressive DisorderTreatment-resistant Bipolar DepressionMajor Depressive Disorder (MDD)Bipolar Disorder (BD)Bipolar Disorder I or IISuicidal Ideation
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorJoshua Rosenblat

About this trial

The goal of this clinical trial is to learn if intravenous (IV) ketamine with Dialectical Behavioural Therapy (DBT) reduces suicidal ideation in individuals with suicidality who have been diagnosed with Borderline Personality Disorder and either Major Depressive Disorder or Bipolar Disorder. The main question it aims to answer is:

Does IV ketamine and DBT produce more rapid and robust improvements in suicidal ideation (SI) severity between baseline and Day 35 compared to IV midazolam and DBT, as measured by changes in the Modified Scale for Suicidal Ideation (MSSI) scores ?

Researchers will compare six IV ketamine infusions and DBT to an active placebo (a look-alike substance that mimics some of ketamine's effects and not others) and DBT to see if IV ketamine with DBT is more effective at reducing SI severity.

Participants will:

* Complete six infusions of either IV ketamine or IV midazolam * Take part in 6 months of DBT (includes both weekly one-on-one sessions, and group sessions, starting week 5 of the trial) * Visit the hospital for scheduled in-person visits * Join a call or videocall for scheduled remote visits * Complete a variety of different mood, cognitive and behavioral assessments

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults between the age of 18 to 70, inclusive;

Meets criteria for BPD, as determined by clinical assessment by a psychiatrist or psychologist and confirmed by the International Personality Disorder Examination (IPDE);

Meets DSM-5 criteria for MDD or BD (I or II), currently experiencing a MDE without psychotic features, as diagnosed by a study psychiatrist or psychologist. Diagnosis will be confirmed using the Mini- International Neuropsychiatric Interview (MINI);

Current MDE must be moderate to severe, as determined by the MADRS score >20 with an inadequate response to two or more guideline-concordant treatment trials as defined by the Antidepressant Treatment History Form-Short Form (ATHF- SF);

Disqualifiers

Past or current history of a psychotic disorder as determined by clinical assessment and MINI;

Current or recent (within the past 3 months) manic or hypomanic episode as determined by clinical assessment via YMRS (score > 12) and the MINI;

Meeting criteria for Moderate to Severe Alcohol or substance use disorders currently or within the past 3 months;

Lifetime history of ketamine use disorder or illicit ketamine use.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Ketamine Hydrochloride

    Drug

    Participants in this arm will receive six ketamine hydrochloride infusions over a month, with doses ranging between 0.5 mg/kg to 0.85 mg/kg

  • Midazolam Hydrochloride

    Drug

    Participants in this arm will receive six midazolam hydrochloride infusions over a month, with doses ranging between 0.02 mg/kg to 0.035 mg/kg

  • Dialectical Behavioral Therapy (DBT)

    Behavioral

    All participants in this trial will receive DBT over six months. Eligible participants will begin with weekly individual sessions, followed by the addition of weekly group sessions beginning in week 5 of the trial.

Treatment groups

120 Participants
are divided into 2 treatment groups
Group A: Ketamine and Dialectical Behavioural TherapyExperimental treatment 2 interventions
Group B: Midazolam and Dialectical Behavioural TherapyPlacebo comparator 2 interventions

Trial outcomes

Primary outcomes

1

Change in suicidal ideation severity using the Modified Scale for Suicidal Ideation (MSSI)

The MSSI is a clinician administered scale used to assess presence or absence of suicidal ideation as well as intensity of suicidal ideation in the previous 48 hours. It consists of 18 items, with each item scored from 0 to 3. Total scores are summed and severity can be categorized as low (0-3), mild (9-20), or severe (\>21).

Time frame
From Baseline to Day 35 (Primary Endpoint)

Secondary outcomes

1

Changes in suicidal ideation severity over a longer period of time using the Modified Scale for Suicidal Ideation (MSSI)

Evaluating changes in MSSI scores between baseline and Month 6 and between baseline and Month 9. The MSSI is a clinician administered scale used to assess presence or absence of suicidal ideation as well as intensity of suicidal ideation in the previous 48 hours. It consists of 18 items, with each item scored from 0 to 3. Total scores are summed and severity can be categorized as low (0-3), mild (9-20), or severe (\>21).

Time frame
From Baseline to Month 6 and Month 9
2

Changes in suicidal behavior (SB) and self-harm (SH) using the Suicide Attempt Self-Injury Interview (SASII)

The SASII is a semi-structured interview that will measure suicidal behavior and self-harm. The SASII is used to collect details of the topography, intent, medical severity, social context, precipitating and concurrent events, and outcomes of non-suicidal self-injury and suicidal behavior during a target time period (in this trial, the target time period will be 'past 3 months').

Time frame
From Baseline to Months 3, 6, and 9
3

Changes in suicidal behavior (SB) and self-harm (SH) using the Lifetime Suicide Attempt Self-Injury Interview (L-SASII)

The L-SASII will be administered at baseline to obtain a count of lifetime history of suicide attempts and non-suicidal self-injury.

Time frame
From Baseline to Months 3, 6, and 9
4

Changes in depression severity using the Montgomery Asberg Depression Rating Scale (MADRS)

The MADRS is a clinician-rated scale measuring depression severity. It consists of 10 items, each scored from 0 (normal) to 6 (severe), for a total possible score of 60. A higher score is indicative of greater depressive severity.

Time frame
From Baseline to Day 35 (Primary Endpoint), Month 6 and Month 9

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Joshua Rosenblat

Lead sponsor

University Health Network, Toronto

Sponsor institution

Source ClinicalTrials.gov
Apply now